Tyra Biosciences Q2 net loss widens to $28.1 mln
Overview
Tyra Biosciences Q2 net loss widens to $28.1 mln from $18.7 mln last year
Basic EPS beats analyst expectations, despite increased R&D and G&A expenses
Co dosed first patient in SURF302 Phase 2 bladder cancer study
Outlook
Tyra expects cash reserves to support operations through at least 2027
Company anticipates Phase 2 readouts in SURF302 and BEACH301
Tyra sees significant opportunity in FGFR3-targeted therapies for bladder cancer
Company plans to dose first child in BEACH301 study in 3Q 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| -$28.10 mln |
|
Q2 Basic EPS | Beat | -$0.47 | -$0.53 (8 Analysts) |
Q2 Operating Income | Beat | -$31.45 mln | -$33.50 mln (8 Analysts) |
Q2 Operating Expenses |
| $31.45 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Tyra Biosciences Inc is $30.00, about 64.2% above its August 13 closing price of $10.75
Press Release: ID:nPnc2yZXMa
Related Articles
Warren Buffett Q2 2025 13F Analysis: Betting on UnitedHealth Again After 14 Years
TradingKey - In Q2 2025, the value of Berkshire Hathaway’s investment portfolio declined from $259.8 billion in Q1 to $257.5 billion, a decrease of 0.89%. Analysis indicates that this drop is primarily driven by a net capital outflow of 0.78%. The outflow may be linked to changing market conditions
Applied Materials Q3 Earnings: AI Demand Soars, but Cautious Guidance Triggers After-Hours Selloff
TradingKey - Applied Materials, Inc. (NASDAQ: AMAT) announced its Q3 FY2025 earnings on August 14, 2025, after market close, reporting strong revenue fueled by AI-related semiconductor demand, which beat expectations. However, cautious Q4 guidance, including EPS below analyst estimates.jpg)
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.
Ethereum Price Prediction: Will ETH Extend the Rally? What’s the Future Trend?
Ethereum's impressive 2025 rally has been largely fueled by inflows from spot ETFs and a surge in institutional holdings, signaling growing confidence in its role as a core asset in the crypto market. However, to officially confirm the start of a new bull cycle, ETH must break above the critical $4,
Japan's economy has fallen back to negative growth after one year. Will yen continue to weaken?
TradingKey - Japan's economic performance is lackluster, with the preliminary annualized quarterly GDP for the first quarter recorded at -0.7%. This marks the first contraction in a year, and the economy may face further impacts from Trump’s tariffs.
